Susan Huyck

5.0k total citations · 2 hit papers
58 papers, 3.6k citations indexed

About

Susan Huyck is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Rheumatology. According to data from OpenAlex, Susan Huyck has authored 58 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Endocrinology, Diabetes and Metabolism, 24 papers in Molecular Biology and 12 papers in Rheumatology. Recurrent topics in Susan Huyck's work include Diabetes Treatment and Management (25 papers), Metabolism, Diabetes, and Cancer (24 papers) and Rheumatoid Arthritis Research and Therapies (12 papers). Susan Huyck is often cited by papers focused on Diabetes Treatment and Management (25 papers), Metabolism, Diabetes, and Cancer (24 papers) and Rheumatoid Arthritis Research and Therapies (12 papers). Susan Huyck collaborates with scholars based in United States, France and Canada. Susan Huyck's co-authors include Steven G. Terra, B Charbonnel, Richard E. Pratley, James P. Mancuso, Urszula Masiukiewicz, Darren K. McGuire, Christopher P. Cannon, Weichung Shih, Samuel Dagogo‐Jack and Francesco Cosentino and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Neurology.

In The Last Decade

Susan Huyck

56 papers receiving 3.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

2020 1.0k citations Christopher P. Cannon, Richard E. Pratley et al. profile →
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

2020 708 citations Darren K. McGuire, Weichung Shih et al. JAMA Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan Huyck United States	23	2.6k	1.3k	981	487	462	58	3.6k
Sylvain Ricard France	21	1.8k 0.7×	847 0.6×	686 0.7×	2.3k 4.6×	230 0.5×	31	4.0k
Andrew Advani Canada	35	960 0.4×	1.6k 1.2×	677 0.7×	781 1.6×	341 0.7×	104	3.9k
Hideki Kishikawa Japan	16	2.0k 0.8×	647 0.5×	559 0.6×	348 0.7×	132 0.3×	47	3.0k
Amy E. Rudolph United States	25	961 0.4×	473 0.4×	887 0.9×	830 1.7×	450 1.0×	40	2.3k
Hideo Izawa Japan	33	568 0.2×	933 0.7×	1.0k 1.1×	2.0k 4.1×	370 0.8×	183	4.0k
Shailaja Suryawanshi United States	16	2.1k 0.8×	1.1k 0.8×	982 1.0×	464 1.0×	98 0.2×	28	3.6k
Tetsuya Babazono Japan	33	1.2k 0.4×	632 0.5×	510 0.5×	649 1.3×	212 0.5×	143	3.3k
Ping Yan China	21	1.3k 0.5×	757 0.6×	601 0.6×	253 0.5×	114 0.2×	55	2.3k
Jeffrey R. Schelling United States	36	458 0.2×	1.3k 1.0×	437 0.4×	469 1.0×	285 0.6×	84	3.2k
Motohide Isono Japan	26	589 0.2×	1.6k 1.2×	340 0.3×	454 0.9×	219 0.5×	43	3.6k

Countries citing papers authored by Susan Huyck

Since Specialization

Citations

This map shows the geographic impact of Susan Huyck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Huyck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Huyck more than expected).

Fields of papers citing papers by Susan Huyck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Huyck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Huyck. The network helps show where Susan Huyck may publish in the future.

Co-authorship network of co-authors of Susan Huyck

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Huyck. A scholar is included among the top collaborators of Susan Huyck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Huyck. Susan Huyck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heijde, Désirée van der, Maxime Dougados, Walter P. Maksymowych, et al.. (2021). Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension. Lara D. Veeken. 61(2). 617–627. 3 indexed citations

Strojek, Krzysztof, A. Shekhar Pandey, Shuai Wang, et al.. (2021). Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV. Diabetes Therapy. 12(4). 1175–1192. 3 indexed citations

McGuire, Darren K., Weichung Shih, Francesco Cosentino, et al.. (2020). Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology. 6(2). 148–148. 708 indexed citations breakdown →

Liu, Jie, Lisa Tarasenko, Annpey Pong, et al.. (2020). Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Current Medical Research and Opinion. 36(8). 1277–1284. 4 indexed citations

Liu, Jie, Lisa Tarasenko, Steven G. Terra, et al.. (2019). Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies. Diabetes and Vascular Disease Research. 16(5). 415–423. 22 indexed citations

Cannon, Christopher P., Darren K. McGuire, Richard E. Pratley, et al.. (2018). DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV). Journal of the American College of Cardiology. 71(11). A1825–A1825. 55 indexed citations

Liu, Jie, Lisa Tarasenko, Annpey Pong, et al.. (2018). Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM). Diabetes. 67(Supplement_1). 1 indexed citations

Huyck, Susan, et al.. (2018). How 4 Companies Became One: Co-development Under an Outsourced Model With Focus on Phase 3 Analysis and Reporting Deliverables. Therapeutic Innovation & Regulatory Science. 53(3). 301–306.

Calle, Roberto A., Jie Liu, Susan Huyck, et al.. (2018). A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin. Diabetes. 67(Supplement_1). 1 indexed citations

10.

Grunberger, George, Jeremy Johnson, Susan Huyck, et al.. (2017). Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Therapy. 9(1). 49–66. 111 indexed citations

11.

Heijde, D. van der, Maxime Dougados, Walter P. Maksymowych, et al.. (2016). LONG-TERM EFFICACY AND TOLERABILITY OF GOLIMUMAB IN ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS : RESULTS OF THE OPEN-LABEL EXTENSION OF A RANDOMIZED, DOUBLE-BLIND STUDY. Clinical and Experimental Rheumatology. 34(4). 752–752. 1 indexed citations

12.

Sieper, Joachim, Martín Rudwaleit, Jan Lenaerts, et al.. (2016). Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. Lara D. Veeken. 55(11). 1946–1953. 14 indexed citations

13.

Heijde, D. van der, Maxime Dougados, Walter P. Maksymowych, et al.. (2016). SAT0388 Long-Term Efficacy and Tolerability of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results of The Open-Label Extension of A Randomized, Double-Blind Study. Annals of the Rheumatic Diseases. 75. 808–809. 2 indexed citations

14.

Hastrup, Nina, Sauzanne Khalilieh, David C. Dale, et al.. (2015). The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects. Cytokine. 72(2). 197–203. 12 indexed citations

15.

Sieper, Joachim, Désirée van der Heijde, Maxime Dougados, et al.. (2015). A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis. Arthritis & Rheumatology. 67(10). 2702–2712. 160 indexed citations

16.

Stocchi, Fabrizio, Olivier Rascol, Robert A. Hauser, et al.. (2014). Phase-3 Clinical Trial of the Adenosine 2a Antagonist Preladenant, Given as Monotherapy, in Patients with Parkinson’s Disease (S7.004). Neurology. 82(10_supplement). 4 indexed citations

17.

Hauser, Robert A., Fabrizio Stocchi, Olivier Rascol, et al.. (2014). Phase-3 Clinical Trials of Adjunctive Therapy with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.087). Neurology. 82(10_supplement). 9 indexed citations

18.

Durez, Patrick, Karel Pavelká, María Alicia Lázaro, et al.. (2014). AB0405 Baseline Predictors of Remission Rates during Golimumab Treatment for Rheumatoid Arthritis in the GO-MORE Study. Annals of the Rheumatic Diseases. 73. 941–941. 1 indexed citations

19.

Gan, Tong J., Jiezhun Gu, Neil Singla, et al.. (2011). Rolapitant for the Prevention of Postoperative Nausea and Vomiting. Anesthesia & Analgesia. 112(4). 804–812. 38 indexed citations

20.

Sherwood, Jill K., et al.. (2007). Particle Size Coarsening Induced by Valve Silicone in a Metered Dose Inhaler. Drug Development and Industrial Pharmacy. 33(2). 155–162. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact